Flagship Pioneering Unveils Laronde to Advance Endless RNA™ - A New Class of Programmable Medicines Capable of Expressing Therapeutic Proteins Inside the Body
Flagship Pioneering unveiled Laronde, a platform company developing Endless RNA™ (eRNA), a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body. Flagship initially committed $50 million to support the development of Laronde’s platform and initial pipeline of new medicines.